ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain, on October 23-27, 2026. ArriVent plans to host a virtual webinar on October 26, 2026 at 8 am ET to discuss the data and ARR-217 program.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.